Details

Autor(en) / Beteiligte

• Majumder, Shounak
• Raimondo, Massimo
• Taylor, William R.
• Yab, Tracy C.
• Berger, Calise K.
• Dukek, Brian A.
• Cao, Xiaoming
• Foote, Patrick H.
• Wu, Chung Wah
• Devens, Mary E.
• Mahoney, Douglas W.
• Smyrk, Thomas C.
• Pannala, Rahul
• Chari, Suresh T.
• Vege, Santhi Swaroop
• Topazian, Mark D.
• Petersen, Bret T.
• Levy, Michael J.
• Rajan, Elizabeth
• Gleeson, Ferga C.
• Abu Dayyeh, Barham
• Nguyen, Cuong C.
• Faigel, Douglas O.
• Woodward, Timothy A.
• Wallace, Michael B.
• Petersen, Gloria
• Allawi, Hatim T.
• Lidgard, Graham P.
• Kisiel, John B.
• Ahlquist, David A.

Titel

Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls

Ist Teil von

• Clinical gastroenterology and hepatology, 2020-03, Vol.18 (3), p.676-683.e3

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2020

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Precursors of pancreatic cancer arise in the ductal epithelium; markers exfoliated into pancreatic juice might be used to detect high-grade dysplasia (HGD) and cancer. Specific methylated DNA sequences in pancreatic tissue have been associated with adenocarcinoma. We analyzed these methylated DNA markers (MDMs) in pancreatic juice samples from patients with pancreatic ductal adenocarcinomas (PDACs) or intraductal papillary mucinous neoplasms (IPMNs) with HGD (cases), and assessed their ability to discriminate these patients from individuals without dysplasia or with IPMNs with low-grade dysplasia (controls). We obtained pancreatic juice samples from 38 patients (35 with biopsy-proven PDAC or pancreatic cystic lesions with invasive cancer and 3 with HGD) and 73 controls (32 with normal pancreas and 41 with benign disease), collected endoscopically from the duodenum after secretin administration from February 2015 through November 2016 at 3 medical centers. Samples were analyzed for the presence of 14 MDMs (in the genes NDRG4, BMP3, TBX15, C13orf18, PRKCB, CLEC11A, CD1D, ELMO1, IGF2BP1, RYR2, ADCY1, FER1L4, EMX1, and LRRC4), by quantitative allele-specific real-time target and signal amplification. We performed area under the receiver operating characteristic curve analyses to determine the ability of each marker, and panels of markers, to distinguish patients with HGD and cancer from controls. MDMs were combined to form a panel for detection using recursive partition trees. We identified a group of 3 MDMs (at C13orf18, FER1L4, and BMP3) in pancreatic juice that distinguished cases from controls with an area under the receiver operating characteristic value of 0.90 (95% CI, 0.83–0.97). Using a specificity cut-off value of 86%, this group of MDMs distinguished patients with any stage of pancreatic cancer from controls with 83% sensitivity (95% CI, 66%–93%) and identified patients with stage I or II PDAC or IPMN with HGD with 80% sensitivity (95% CI, 56%–95%). We identified a group of 3 MDMs in pancreatic juice that identify patients with pancreatic cancer with an area under the receiver operating characteristic value of 0.90, including patients with early stage disease or advanced precancer. These DNA methylation patterns might be included in algorithms for early detection of pancreatic cancer, especially in high-risk cohorts. Further optimization and clinical studies are needed.